Periodic Reporting for period 4 - ALLERGUT (Mucosal Tolerance and Allergic Predisposition: Does it all start in the gut?)
Reporting period: 2022-01-01 to 2023-10-31
In this project, we hypothesize that alterations in the immune system due to differences in microbial compositions is a common and underlying cause for the above described observations. In particular, the immune system of the gastrointestinal tract where microbial burden is highest and were a big surface area allows for various interactions between the host and its microbial symbionts is of particular importance. Based on our previous results based on in vivo animal models we hypothesize that a specialized population of regulatory T cells (so-called type 3 Tregs) co-expressing the transcription factors Foxp3 and RORgt is a central player in this process for the following reasons: a) Type 3 Tregs develop after weaning and reside within the intestinal tract b) Type 3 Tregs have the highest frequencies where microbial exposure is highest (colon>small intestine>secondary lymphoid tissues associated to the intestinal tract>spleen/distal lymph nodes>thymus) c) Type 3 Tregs are absent in germfree or broad spectrum antibiotic-treated animals and d) genetic ablation of Type 3 Tregs leads to exaggerated type 2 immune responses also found in germfree conditions. Assessing the microbial habitat within the intestinal tract is still a very difficult task because interindividual variety is high and complex interdependent interactions between hundreds of microbial species cannot be easily studied in vitro because many of these species are not yet cultivable. Therefore, type 3 Tregs may serve as a faithful readout for inefficient induction of intestinal homeostasis which can affect both local and systemic diseases associated to a loss of immunological tolerance.
In this project we aim to identify thus both microbial and host-intrinsic pathways that positively or negatively regulate the induction and maintenance of type 3 Tregs. We anticipate that this knowledge can serve as a useful tool to diagnose and in the future possibly also prevent allergic and other diseases associated to a loss of immunological tolerance to foreign antigens.
So far, we have been able to reveal a key role for dendritic cells in regulating the fate decisions for the differentiation of Type 3 Tregs from naïve T cells. Notably, dendritic cells with constitutively activated CD40 signaling fail to induced type 3 Tregs and induced efficient oral tolerance (assessed in a collaboration). In line with this result, we found recently that genetic ablation of alternative NF-kB signaling in dendritic cells leads to an inefficient induction of type 3 Tregs in vivo suggesting again impaired oral tolerance. Interestingly, we observed a systemic accumulation of ‘conventional’ Tregs across all examined organs. These Tregs seem to have a tissue Treg phenotype characterized by high Gata3 and interleukin 33 receptor expression. Nevertheless, we did not find any hint for IL-33 being a driver of Treg accumulation in vivo. As the tissue Treg phenotype suggested self-reactivity, we checked whether these mice are protected from autoimmune diseases. Indeed, ablation of RelB in dendritic cells almost completely protects mice from a murine model of multiple sclerosis (MS) in a Treg-dependent manner. These data have been published recently in a peer reviewed journal (Andreas et al., J Immunol. 2019).
As high Gata3 expression in Tregs driven by enhanced interleukin 4 receptor signaling has been proposed to render Tregs pathological cells in food allergy we will now address whether mice lacking RelB in dendritic cells show more severe food allergy including life-threatening anaphylactic reactions. Furthermore, we are currently addressing the underlying mechanisms for the observed changes on T cells in the absence of RelB in dendritic cells.